According to the study, 3,603 children younger than nine months were screened using HemoTypeSC to show the feasibility of adding newborn screening into existing primary health-care immunizations with rapid testing. This reinforces access to patients with sickle cell in poor communities, a shift from developed countries with better nutrition, bigger financial budgets, and infectious disease vaccines having prominent accessibility, according to the Fogarty International Center at the National Institutes of Health.
The integration of newborn screening into existing primary healthcare immunization programs is feasible and can rapidly be implemented with limited resources, according to a study led by professor Obiageli Nnodu, director of the Centre of Excellence for Sickle Cell Disease Research and Training at Nigeria’s University of Abuja. To realistically screen every newborn for sickle cell disease, Nnodu says a simple, reliable and affordable point-of-care rapid test will be deployed at immunization clinics, a place most newborns will visit soon after birth. One such example is the HemoTypeSC) from Silver Lake Research, a diagnostics firm based in southern California.